We are live on ! Find out more
SGA

Sector Gamma AS Portfolio holdings

AUM $423M
1-Year Est. Return 17.56%
This Fund
S&P 500
This Quarter Est. Return
+9.59%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$688M
AUM Growth
+$59.1M
Cap. Flow
+$2.64M
Cap. Flow %
0.38%
Top 10 Hldgs %
65.8%
Holding
28
New
2
Increased
16
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$15.3M
2
ABT icon
Abbott
ABT
+$9.9M
3
GILD icon
Gilead Sciences
GILD
+$6.65M
4
BMY icon
Bristol-Myers Squibb
BMY
+$5.82M
5
THC icon
Tenet Healthcare
THC
+$5.64M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$29.2M
2
LLY icon
Eli Lilly
LLY
+$15.2M
3
MASI
Masimo
MASI
+$5.21M
4
ELV icon
Elevance Health
ELV
+$4.53M
5
UTHR icon
United Therapeutics
UTHR
+$3.92M

Sector Composition

Rank Sector Weight
1 Healthcare 98.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABT icon
1
Abbott
ABT
$175B
$74.7M 10.86%
1,537,342
+218,700
+17% +$9.9M
BAX icon
2
Baxter International
BAX
$11.7B
$64.8M 9.42%
1,070,333
+34,100
+3% +$1.94M
BMY icon
3
Bristol-Myers Squibb
BMY
$124B
$49.6M 7.2%
889,390
+107,000
+14% +$5.82M
RVTY icon
4
Revvity
RVTY
$12.3B
$43M 6.25%
631,308
+7,900
+1% +$491K
BSX icon
5
Boston Scientific
BSX
$65.4B
$39.8M 5.79%
1,437,480
+13,600
+1% +$361K
LLY icon
6
Eli Lilly
LLY
$1.05T
$39.1M 5.69%
475,250
-186,100
-28% -$15.2M
GILD icon
7
Gilead Sciences
GILD
$167B
$38.8M 5.64%
548,390
+99,900
+22% +$6.65M
IRWD icon
8
Ironwood Pharmaceuticals
IRWD
$635M
$34.6M 5.03%
2,188,718
-128,571
-6% -$1.87M
SHPG
9
DELISTED
Shire pic
SHPG
$34.4M 4.99%
207,861
+27,100
+15% +$4.74M
ELV icon
10
Elevance Health
ELV
$80.9B
$33.8M 4.91%
179,410
-25,200
-12% -$4.53M
IART icon
11
Integra LifeSciences
IART
$1.5B
$26.9M 3.91%
493,230
+5,000
+1% +$239K
BIO icon
12
Bio-Rad Laboratories Class A
BIO
$8.15B
$26M 3.78%
114,942
+900
+0.8% +$196K
PRGO icon
13
Perrigo
PRGO
$1.48B
$22.1M 3.22%
293,140
+45,800
+19% +$3.28M
MCK icon
14
McKesson
MCK
$98.5B
$19.1M 2.78%
116,100
+900
+0.8% +$136K
MASI
15
DELISTED
Masimo
MASI
$18.4M 2.67%
201,418
-56,800
-22% -$5.21M
PDCO
16
DELISTED
Patterson Companies, Inc.
PDCO
$18.1M 2.64%
386,232
– –
BIIB icon
17
Biogen
BIIB
$30.4B
$15.7M 2.28%
+57,800
New +$15.3M
CI icon
18
Cigna
CI
$74.5B
$14.1M 2.05%
84,270
– –
LH icon
19
Labcorp
LH
$23.2B
$13.1M 1.9%
98,940
+1,280
+1% +$157K
THC icon
20
Tenet Healthcare
THC
$16.8B
$11.1M 1.62%
575,180
+323,100
+128% +$5.64M
LXRX icon
21
Lexicon Pharmaceuticals
LXRX
$1.06B
$10.2M 1.49%
622,655
+290,355
+87% +$4.5M
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$10.2M 1.49%
605,545
-151,220
-20% -$2.3M
LPNT
23
DELISTED
LifePoint Health, Inc.
LPNT
$10.1M 1.46%
149,714
-15,000
-9% -$948K
IPXL
24
DELISTED
Impax Laboratories, Inc.
IPXL
$9.49M 1.38%
589,311
+55,000
+10% +$812K
ACH
25
Accendra Health
ACH
$266M
$5.66M 0.82%
175,874
+30,000
+21% +$985K
1
2

Similar funds

AFWM
AMJ Financial Wealth Management Leesburg, Virginia $424M AUM 37.24% 1-Year Est. Return
MP
McDonald Partners Cleveland, Ohio $424M AUM 29.07% 1-Year Est. Return
DS
Dalal Street West Lake Hills, Texas $423M AUM 115.19% 1-Year Est. Return
RS
Retirement Solution Redmond, Washington $423M AUM 16.83% 1-Year Est. Return
DF
Dunhill Financial London, United Kingdom $424M AUM 16.79% 1-Year Est. Return
OGM
OnyxPoint Global Management New York $424M AUM 84.95% 1-Year Est. Return
CPIM
Cypress Point Investment Management Mill Valley, California $424M AUM
MPPLM
Midwest Professional Planners Ltd (MPPL) Wausau, Wisconsin $425M AUM 28.89% 1-Year Est. Return

Sector Gamma AS's Q2 2017 Portfolio in Review

As of Q2 2017, Sector Gamma AS held 28 positions worth $688M, up 9.4% from $629M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sector Gamma AS's Q2 2017 filing shows 2 new, 16 increased, 6 reduced and 2 closed positions. Its largest new stake was Biogen: 57,800 shares worth $15.7M. The largest sale was Vertex Pharmaceuticals, an estimated $29.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

  • Sector Gamma AS's largest Q2 2017 buy was Biogen: 57,800 shares worth $15.7M.
  • Sector Gamma AS added most to Abbott in Q2 2017, an estimated $9.9M increase.
  • Sector Gamma AS's biggest Q2 2017 reduction was Eli Lilly, cutting an estimated $15.2M.
  • Sector Gamma AS fully exited Vertex Pharmaceuticals in Q2 2017, selling an estimated $29.2M.
  • Sector Gamma AS's ten largest holdings make up 66% of its $688M portfolio in Q2 2017.
  • Sector Gamma AS opened 2 new positions and closed 2 in Q2 2017.
  • Sector Gamma AS's portfolio value rose 9.4% quarter-over-quarter to $688M.

Based on Sector Gamma AS's 13F filing for Q2 2017, filed 14 Aug 2017.